SARS-CoV-2

Zika virus
#AI #SARS-CoV-2 #virus

New AI-powered database set to accelerate virus research

UK researchers have launched a new platform described as ‘the most comprehensive human virus protein database’ in the world, it has been revealed.  Viro3D, which was developed by researchers at the MRC-University of Glasgow Centre for Virus Research, uses AI to offer new perspectives on viruses, allowing… Read More

#News

Covid-19
#Covid-19 #Immunology / Virology & Vaccines #Preclinical development #Rocketvax #SARS-CoV-2

Robust preclinical results for live-attenuated SARS-CoV-2 vaccine

Live-attenuated SARS-CoV-2 vaccine candidate, OTS-228, has demonstrated exceptional safety, efficacy, and genomic stability in preclinical animal models.  The vaccine was developed under the scientific leadership of Professor Dr Volker Thiel, Chief Scientist of Rocketvax and Professor of Virology at the University of Bern.  The latest… Read More

#News #Trending News

Patient receiving vaccine
#Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Korea #SARS-CoV-2

Adjuvanted Covid-19 vaccine elicits stronger immune response

Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. The interim results show that GBP510/AS03 had an acceptable safety profile and induced stronger antibody responses when compared with ChAdOx1-S GBP510 is a recombinant… Read More

#News

Long Covid
#Covid-19 #Immunology #Long Covid #Psychiatry #SARS-CoV-2

New post-Covid study links infection and retrovirus 

A Translational Psychiatry publication indicates that SARS-CoV-2 infection, even when unnoticed or asymptomatic, can have an influence on the activation of the Human Endogenous Retrovirus W (W-ENV) protein in psychotic patients, in a context of innate immune inflammation.   GeNeuro, a biopharmaceutical company developing treatments… Read More

#Covid-19 #News

T cell attacking Covid-19
#Covid-19 #Covid-19 vaccine #Immune response #Immunology / Virology & Vaccines #SARS-CoV-2 #T cell activation

Covid-19 causes long-term damage to the immune system

New findings suggest that the SARS-CoV-2 virus damages an important immune-cell response. The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. Read More

#News #Trending News

Dr Nevan Krogran receives Legion of Honour
#Awards #Covid-19 #Institut Pasteur #SARS-CoV-2 #UCSF

Covid-19 research group founder receives Legion of Honor 

Dr Nevan Krogan, Founder of the UC San Francisco (UCSF) Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG) and Director of QBI, has been awarded France’s Legion of Honor.  The award was given for forming an international research collaboration and for scientific contributions utilising a… Read More

#Covid-19 #News

Lipid nanoparticle mRNA vaccine entering a human cell
#Covid-19 #Covid-19 treatment #hACE2 #mRNA #SARS-CoV-2

Could mRNA become a ‘universal’ Covid-19 treatment? 

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses.  A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2… Read More

#Covid-19 #News

Automated pipetting
#App note #Automated liquid handling #Automation / robotics #Clinical diagnostics #Covid-19 #Liquid handling #SARS-CoV-2

New App Note on automated Sars-CoV-2 clinical diagnostics

A new App Note is now available, sponsored by Analytik Jena: Rapid Development of Automated Sars-CoV-2 Clinical Diagnostics. Download to learn about: How to create and share an automated workflow for rapid development and validation of SARS-CoV-2 clinical diagnostics. The highly scalable liquid handling platform, CyBio FeliX for clinical… Read More

#News

App Note: Rapid Development of Automated Sars-CoV-2 Clinical Diagnostics
#App note #Automated liquid handling #Automation / robotics #Clinical diagnostics #Covid-19 #Liquid handling #SARS-CoV-2

Rapid development of automated Sars-CoV-2 clinical diagnostics

Download the App Note to learn about: How to create and share an automated workflow for rapid development and validation of SARS-CoV-2 clinical diagnostics. The highly scalable liquid handling platform, CyBio FeliX for clinical diagnostics – it provides magnetic bead-based nucleic acid extraction, eliminating laborious and time-consuming column-based binding and… Read More

#App Notes #Intelligence #Resources

SARS-CoV-2 virus particles
#Antibodies #Biomarkers #Clinical trials #Coronavirus #Covid-19 #Drug development #SARS-CoV-2

SARS-CoV-2 antigen levels could predict patient outcomes

The amount of SARS-CoV-2 antibodies in the blood of patients hospitalised with Covid-19 could be used to predict illness severity and other clinical outcomes.  A new study, published in the Annals of Internal Medicine, shows that higher levels of viral antigen in the blood, which… Read More

#Covid-19 #News

#Biomanufacturing #Corning Life Sciences #Drug discovery #Immunology / Virology & Vaccines #Life sciences #SARS-CoV-2

Optimising vaccine production through customisation

Listen to this article on the DDW Podcast: An expert’s view by John Yoshi Shyu, Ph.D. Corning Life Sciences. Most vaccines are manufactured using technology devised fifty or more years ago, in manufacturing plants that are sometimes even older. The vaccine production process is continually refreshed by new tools and technologies,… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Antibodies #Biopharmaceuticals #Biotherapeutics #Covid-19 #SARS-CoV-2

Helping Indian biotherapeutic companies advance novel therapeutics

Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles… Read More

#News

#Covid-19 #Drug development #Drug discovery #Pharmaceuticals #RNA #SARS-CoV-2

SARS-CoV-2 spike protein induces lipid stripping from cell membrane

Scientists at the Institut Laue-Langevin (ILL), in collaboration with the Paul Scherrer Institut (PSI), the Institut de Biologie Structurale (IBS) and the Australian Nuclear Science and Technology Organisation (ANSTO), have published new data on how the SARS-CoV-2 spike protein interacts with mammalian lung cell membranes, allowing the viral… Read More

#Covid-19 #News #Trending News

#Anti-viral drug screening #Assay validation #Automated workflows #Drug screening #High throughput screening #Immunology / Virology & Vaccines #Microplate readers #SARS-CoV-2

Webinar: Improving work rate, productivity and getting to market faster

We know there are operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is slow and expensive, with high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the current pandemic is prompting a… Read More

#News

#Anti-viral drug screening #Assay validation #Automated workflows #Drug screening #SARS-CoV-2

How to improve data quality and speed, and reduce cycle time

The Covid-19 pandemic has promoted global efforts to develop antiviral treatments against SARS-CoV-2. During this process, the endemic operational vulnerabilities of the drug discovery process have been highlighted. The reality is: bringing new drugs to the market is associated with high costs, high failure rates and long cycle times…and this… Read More

#News

#Anti-viral drug screening #Assay validation #Automated workflows #Drug screening #High throughput screening #Immunology / Virology & Vaccines #Microplate readers #SARS-CoV-2

How to improve work rate, productivity and get to market faster

Research laboratories have not fundamentally changed since the 1960s, says BMG LABTECH. Despite improvements in technology such as high-throughput screening and computational drug design, drug discovery is becoming slower and more expensive over time. Covid-19 highlighted operational vulnerabilities which are driving a fundamental reassessment of strategic priorities. In fact, says… Read More

#Editor's Choice #News